Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463540 | 1.00 | CHRM3 (0.35) | CHRM3L3MBTL1KMT2AHTTAR | |
| SCHEMBL11997996 | 1.00 | CHRM3 (0.35) | CHRM3L3MBTL1KMT2AHTTAR | |
| SCHEMBL13452774 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL12572936 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL20093387 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL23371066 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL21398646 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL15786185 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL17835201 | 0.86 | — | — | |
| SCHEMBL18269015 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220411434-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220117952-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20110152497-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CHRM3 11/4885L3MBTL1 4240/4885KMT2A 2435/4885 |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | CHRM3 258/4885L3MBTL1 1383/4885KMT2A 3704/4885 |
| US-20220411434-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | CHRM3 4803/4885L3MBTL1 3650/4885KMT2A 3175/4885 |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | CHRM3 2462/4885L3MBTL1 3423/4885KMT2A 3692/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885L3MBTL1 4285/4885KMT2A 4371/4885 |
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | HAVCR2, EIF2AK2, HSP90B1 | CHRM3 4876/4885L3MBTL1 2154/4885KMT2A 2756/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | CHRM3 2204/4885L3MBTL1 4018/4885KMT2A 3297/4885 |
| US-20220117952-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | HAVCR2, EIF2AK2, HPN | CHRM3 4864/4885L3MBTL1 2243/4885KMT2A 2881/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM3 179/4885L3MBTL1 4285/4885KMT2A 4371/4885 |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | ZC3HAV1, ZC3HAV1L, GDI1 | CHRM3 4758/4885L3MBTL1 3889/4885KMT2A 3406/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CHRM3 4032/4885L3MBTL1 3099/4885KMT2A 2868/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | CHRM3 2819/4885L3MBTL1 3035/4885KMT2A 3889/4885 |
| US-20110152497-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | CHRM3 2119/4885L3MBTL1 4790/4885KMT2A 1825/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | CHRM3 1654/4885L3MBTL1 1883/4885KMT2A 4757/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CHRM3 4032/4885L3MBTL1 3099/4885KMT2A 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.